Seattle Genetics (SGEN)

57.43 +3.04 (5.59%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (2/6/19 *Est.)
- M&A (3/31/18 *Est)

Latest Headlines

Form 8-K SEATTLE GENETICS INC For: Nov 16 November 16, 2018 5:02 PM - SEC Filing Seattle Genetics (SGEN) Reports FDA Approval of ADCETRIS (Brentuximab Vedotin) in Combination with Chemotherapy November 16, 2018 10:53 AM - StreetInsider Seattle Genetics Announces FDA Approval of ADCETRIS® (Brentuximab Vedotin) in Combination with Chemotherapy for Adults with Previously Untreated Systemic Anaplastic Large Cell Lymphoma or Other CD30- November 16, 2018 10:52 AM - BizWire Seattle Genetics (SGEN) Granted FDA Approves for Peripheral T-cell Lymphoma Treatment November 16, 2018 10:49 AM - StreetInsider Seattle Genetics (SGEN) Announces FDA Granted Breakthrough Therapy Designation to ADCETRIS for Frontline Peripheral T-Cell Lymphomas November 15, 2018 8:02 AM - StreetInsider FDA Grants Breakthrough Therapy Designation to ADCETRIS® (Brentuximab Vedotin) for Frontline Peripheral T-Cell Lymphomas November 15, 2018 8:00 AM - BizWire Baker Bros. Advisors 13F for Quarter Ended Sept. 30, 2018 November 14, 2018 4:55 PM - StreetInsider Seattle Genetics (SGEN) Commences Phase 1 Clinical Trial of SEA-BCMA for Patients with Relapsed or Refractory Multiple Myeloma November 14, 2018 8:06 AM - StreetInsider Seattle Genetics Initiates Phase 1 Clinical Trial of SEA-BCMA for Patients with Relapsed or Refractory Multiple Myeloma November 14, 2018 8:00 AM - BizWire Form 4 SEATTLE GENETICS INC For: Nov 08 Filed by: SIEGALL CLAY B November 9, 2018 5:55 PM - SEC Filing Seattle Genetics to Present at the Credit Suisse 27th Annual Healthcare Conference November 6, 2018 8:00 AM - BizWire Seattle Genetics (SGEN) Reports Supplemental Biologics License Application Submission for ADCETRIS (Brentuximab Vedotin) November 5, 2018 8:05 AM - StreetInsider Seattle Genetics Submits Supplemental Biologics License Application for ADCETRIS® (Brentuximab Vedotin) in Frontline Treatment of CD30-Expressing Peripheral T-Cell Lymphomas November 5, 2018 8:00 AM - BizWire Form 4 SEATTLE GENETICS INC For: Oct 30 Filed by: AKKARAJU SRINIVAS November 1, 2018 5:55 PM - SEC Filing Seattle Genetics Announces More Than 30 Presentations at ASH 2018 Highlighting Progress with Broad ADCETRIS® (Brentuximab Vedotin) Development Program November 1, 2018 4:05 PM - BizWire Form 10-Q SEATTLE GENETICS INC For: Sep 30 October 26, 2018 4:23 PM - SEC Filing Pre-Open Movers 10/26: (MLNX) (LOGM) (EXPE) Higher; (SGYP) (AMZN) (GOOGL) Lower (more...) October 26, 2018 9:20 AM - StreetInsider BofA/Merrill Lynch Downgrades Seattle Genetics (SGEN) to Underperform, Seeks to Await E2 Contribution October 26, 2018 9:11 AM - StreetInsider Seattle Genetics Announces Multiple Data Presentations Evaluating ADCETRIS® (Brentuximab Vedotin) in Patients with Hodgkin Lymphoma at ISHL 2018 October 26, 2018 8:00 AM - BizWire Seattle Genetics (SGEN) PT Lowered to $92 at RBC Capital October 26, 2018 7:35 AM - StreetInsider Seattle Genetics (SGEN) PT Lowered to $66 at Piper Jaffray October 26, 2018 6:52 AM - StreetInsider Seattle Genetics (SGEN) PT Lowered to $90 at Barclays October 26, 2018 4:01 AM - StreetInsider After-Hours Stock Movers 10/25: (MAT) (EXPE) (CMG) Higher; (SGYP) (AMZN) (GOOGL) Lower (more...) October 25, 2018 5:53 PM - StreetInsider Seattle Genetics (SGEN) Sinks Following Q3 Results, Q4 Outlook October 25, 2018 5:40 PM - StreetInsider Form 8-K SEATTLE GENETICS INC For: Oct 25 October 25, 2018 4:09 PM - SEC Filing Seattle Genetics Reports Third Quarter 2018 Financial Results October 25, 2018 4:02 PM - BizWire Form 4 SEATTLE GENETICS INC For: Oct 08 Filed by: SIEGALL CLAY B October 9, 2018 8:14 PM - SEC Filing Genmab and Seattle Genetics Announce Tisotumab Vedotin Data to be Presented at ESMO 2018 Congress October 8, 2018 6:52 PM - StreetInsider Genmab and Seattle Genetics Announce Tisotumab Vedotin Data to Be Presented at ESMO 2018 Congress October 8, 2018 6:50 PM - BizWire Seattle Genetics to Host Conference Call and Webcast Discussion of Third Quarter Financial Results on October 25, 2018 October 3, 2018 8:00 AM - BizWire Research Report Identifies Ultragenyx Pharmaceutical, Helmerich & Payne, Buckeye Partners, Covanta Holding, Summit Midstream Partners, LP, and Seattle Genetics with Renewed Outlook — Fundamental October 3, 2018 7:50 AM - Globe NewsWire Seattle Genetics (SGEN) PT Raised to $95 at Barclays October 3, 2018 4:22 AM - StreetInsider Seattle Genetics (SGEN) PT Raised to $94 at Guggenheim October 2, 2018 12:37 PM - StreetInsider Seattle Genetics (SGEN) PT Raised to $82 at Cowen October 1, 2018 12:38 PM - StreetInsider Seattle Genetics (SGEN) PT Raised to $105 at Leerink Partners October 1, 2018 11:21 AM - StreetInsider Seattle Genetics (SGEN) PT Raised to $98 at RBC Capital October 1, 2018 11:14 AM - StreetInsider Form 8-K SEATTLE GENETICS INC For: Oct 01 October 1, 2018 6:58 AM - SEC Filing Seattle Genetics (SGEN), Takeda Pharmaceutical Report Positive Results from Phase 3 ECHELON-2 Clinical Trial Evaluating ADCETRIS (Brentuximab Vedotin) October 1, 2018 6:48 AM - StreetInsider Seattle Genetics and Takeda Announce Positive Results from Phase 3 ECHELON-2 Clinical Trial Evaluating ADCETRIS® (Brentuximab Vedotin) in Frontline CD30-Expressing Peripheral T-Cell Lymphoma October 1, 2018 6:45 AM - BizWire Leerink Partners Starts Seattle Genetics (SGEN) at Outperform September 24, 2018 4:30 PM - StreetInsider Seattle Genetics (SGEN) Announces ADCETRIS Approval in Japan for Frontline Hodgkin Lymphoma September 21, 2018 10:48 AM - StreetInsider Seattle Genetics Announces ADCETRIS® (Brentuximab Vedotin) Approval in Japan for Frontline Hodgkin Lymphoma September 21, 2018 10:48 AM - BizWire Form 4 SEATTLE GENETICS INC For: Sep 17 Filed by: SIEGALL CLAY B September 19, 2018 6:37 PM - SEC Filing BioClin Therapeutics Announces New Leadership to Advance Late-Stage Bladder Cancer Development Program September 19, 2018 4:27 PM - BizWire BioClin Therapeutics Announces New Leadership to Advance Late-Stage Bladder Cancer Development Program September 18, 2018 4:06 PM - BizWire Guggenheim Starts Seattle Genetics (SGEN) at Buy September 17, 2018 4:34 PM - StreetInsider Form 4 SEATTLE GENETICS INC For: Sep 07 Filed by: DANSEY ROGER D September 11, 2018 7:31 PM - SEC Filing Form 4 SEATTLE GENETICS INC For: Sep 07 Filed by: HIMES VAUGHN B September 11, 2018 7:26 PM - SEC Filing Piper Jaffray Assumes Seattle Genetics (SGEN) at Neutral September 6, 2018 4:10 PM - StreetInsider Form 4 SEATTLE GENETICS INC For: Aug 30 Filed by: SIMPSON TODD E September 4, 2018 9:00 PM - SEC Filing Form 4 SEATTLE GENETICS INC For: Aug 30 Filed by: LIU JEAN I September 4, 2018 8:57 PM - SEC Filing Form 4 SEATTLE GENETICS INC For: Aug 30 Filed by: HIMES VAUGHN B September 4, 2018 8:55 PM - SEC Filing Form 4 SEATTLE GENETICS INC For: Aug 30 Filed by: DANSEY ROGER D September 4, 2018 8:51 PM - SEC Filing Form 4 SEATTLE GENETICS INC For: Aug 30 Filed by: Cline Darren S September 4, 2018 8:43 PM - SEC Filing Form 4 SEATTLE GENETICS INC For: Aug 30 Filed by: SIEGALL CLAY B September 4, 2018 8:38 PM - SEC Filing Seattle Genetics to Present at the Morgan Stanley Global Healthcare Conference September 4, 2018 8:00 AM - BizWire Form 4 SEATTLE GENETICS INC For: Aug 27 Filed by: SIMPSON TODD E August 29, 2018 7:41 PM - SEC Filing Form 4 SEATTLE GENETICS INC For: Aug 27 Filed by: SIEGALL CLAY B August 29, 2018 7:40 PM - SEC Filing Form 4 SEATTLE GENETICS INC For: Aug 27 Filed by: LIU JEAN I August 29, 2018 7:38 PM - SEC Filing Form 4 SEATTLE GENETICS INC For: Aug 27 Filed by: HIMES VAUGHN B August 29, 2018 7:36 PM - SEC Filing Form 4 SEATTLE GENETICS INC For: Aug 27 Filed by: Cline Darren S August 29, 2018 7:33 PM - SEC Filing Harpoon Therapeutics Expands Board of Directors August 27, 2018 8:30 AM - BizWire Form 4 SEATTLE GENETICS INC For: Aug 21 Filed by: SIEGALL CLAY B August 23, 2018 8:03 PM - SEC Filing Full Article List